Policy & Regulation
Clinical Ink Implements COVID-19 Therapy Trial in Three Weeks
2 June 2020 - - US-based clinical trial technology company Clinical Ink has helped expedite the study of a treatment for cytokine storm, the immunological reaction associated with severe cases of COVID-19, the company said.

Clinical Ink purpose-built and deployed the electronic study environment in just 15 business days, including the study's full schedule of assessments, a full complement of edit checks and logic, and complete user acceptance testing.

The flexibility of the Lumenis technology platform and its ability to be adapted and deployed quickly have minimized the timeline for this 300-patient, 36-site study.

The drug under investigation is a novel intravenous anti-inflammatory.

This new molecular entity is a granulocyte macrophage colony stimulating factor antagonist that already has Phase I safety data from a clinical trial in volunteers and patients with ankylosing spondylitis.

Clinical Ink, a global clinical technology company, offers data certainty from source to submission.

Our Lumenis eSource clinical technology and configurable direct data capture, eCOA, ePRO, and eConsent modules, a suite of solutions for capturing and integrating electronic data from sites, clinicians, and patients at its source, naturally enhance your clinical trial workflow by reducing manual labor, providing anytime, anywhere data access, and saving resources as your trials progress.
Login
Username:

Password: